57 related articles for article (PubMed ID: 37436606)
41. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?
Koay EJ; Odisio BC; Javle M; Vauthey JN; Crane CH
Hepatobiliary Surg Nutr; 2017 Apr; 6(2):105-116. PubMed ID: 28503558
[TBL] [Abstract][Full Text] [Related]
42. Using the National Cancer Database for Outcomes Research: A Review.
Boffa DJ; Rosen JE; Mallin K; Loomis A; Gay G; Palis B; Thoburn K; Gress D; McKellar DP; Shulman LN; Facktor MA; Winchester DP
JAMA Oncol; 2017 Dec; 3(12):1722-1728. PubMed ID: 28241198
[TBL] [Abstract][Full Text] [Related]
43. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.
Saha SK; Zhu AX; Fuchs CS; Brooks GA
Oncologist; 2016 May; 21(5):594-9. PubMed ID: 27000463
[TBL] [Abstract][Full Text] [Related]
44. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS; Wo JY; Yeap BY; Ben-Josef E; McDonnell EI; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Goyal L; Murphy JE; Javle MM; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Yoon SS; Tanabe KK; Ferrone CR; Ryan DP; DeLaney TF; Crane CH; Zhu AX
J Clin Oncol; 2016 Feb; 34(5):460-8. PubMed ID: 26668346
[TBL] [Abstract][Full Text] [Related]
45. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.
Tao R; Krishnan S; Bhosale PR; Javle MM; Aloia TA; Shroff RT; Kaseb AO; Bishop AJ; Swanick CW; Koay EJ; Thames HD; Hong TS; Das P; Crane CH
J Clin Oncol; 2016 Jan; 34(3):219-26. PubMed ID: 26503201
[TBL] [Abstract][Full Text] [Related]
46. Intrahepatic cholangiocarcinoma.
Brown KM; Parmar AD; Geller DA
Surg Oncol Clin N Am; 2014 Apr; 23(2):231-46. PubMed ID: 24560108
[TBL] [Abstract][Full Text] [Related]
47. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
[TBL] [Abstract][Full Text] [Related]
48. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
[TBL] [Abstract][Full Text] [Related]
49. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma.
Kim JH; Won HJ; Shin YM; Kim KA; Kim PN
AJR Am J Roentgenol; 2011 Feb; 196(2):W205-9. PubMed ID: 21257864
[TBL] [Abstract][Full Text] [Related]
50. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients.
Chen YX; Zeng ZC; Tang ZY; Fan J; Zhou J; Jiang W; Zeng MS; Tan YS
BMC Cancer; 2010 Sep; 10():492. PubMed ID: 20840777
[TBL] [Abstract][Full Text] [Related]
51. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools.
Raval MV; Bilimoria KY; Stewart AK; Bentrem DJ; Ko CY
J Surg Oncol; 2009 Jun; 99(8):488-90. PubMed ID: 19466738
[TBL] [Abstract][Full Text] [Related]
52. NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
Benson AB; Abrams TA; Ben-Josef E; Bloomston PM; Botha JF; Clary BM; Covey A; Curley SA; D'Angelica MI; Davila R; Ensminger WD; Gibbs JF; Laheru D; Malafa MP; Marrero J; Meranze SG; Mulvihill SJ; Park JO; Posey JA; Sachdev J; Salem R; Sigurdson ER; Sofocleous C; Vauthey JN; Venook AP; Goff LW; Yen Y; Zhu AX
J Natl Compr Canc Netw; 2009 Apr; 7(4):350-91. PubMed ID: 19406039
[No Abstract] [Full Text] [Related]
53. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.
Khan SA; Toledano MB; Taylor-Robinson SD
HPB (Oxford); 2008; 10(2):77-82. PubMed ID: 18773060
[TBL] [Abstract][Full Text] [Related]
54. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.
Endo I; Gonen M; Yopp AC; Dalal KM; Zhou Q; Klimstra D; D'Angelica M; DeMatteo RP; Fong Y; Schwartz L; Kemeny N; O'Reilly E; Abou-Alfa GK; Shimada H; Blumgart LH; Jarnagin WR
Ann Surg; 2008 Jul; 248(1):84-96. PubMed ID: 18580211
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
56. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.
Burke EC; Jarnagin WR; Hochwald SN; Pisters PW; Fong Y; Blumgart LH
Ann Surg; 1998 Sep; 228(3):385-94. PubMed ID: 9742921
[TBL] [Abstract][Full Text] [Related]
57. Comparing Survival After Resection, Ablation, and Radiation in Small Intrahepatic Cholangiocarcinoma.
Masoud SJ; Rhodin KE; Kanu E; Bao J; Eckhoff AM; Bartholomew AJ; Howell TC; Aykut B; Kosovec JE; Palta M; Befera NT; Kim CY; Herbert G; Shah KN; Nussbaum DP; Blazer DG; Zani S; Allen PJ; Lidsky ME
Ann Surg Oncol; 2023 Oct; 30(11):6639-6646. PubMed ID: 37436606
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
